US allows increased production of Takeda’s ADHD drug to address shortage

Sept 4 (Reuters) – The U.S. Drug Enforcement Administration (DEA) has increased the production limit for Takeda Pharmaceutical’s (4502.T), opens new tab ADHD drug Vyvanse and its generic versions by about 24% to address the medicine’s ongoing shortage in the United States. The raised production limit follows the Food and Drug Administration’s request in July,…

Read More

The brain’s balancing system

Summary: A finding by neuroscientists could open doors to new treatments for a range of psychiatric and neurological disorders attributed to dysfunctions in specific dopamine pathways.

Read More

Youth mental health outcomes varied during pandemic, study finds

The COVID-19 pandemic caused many disruptions in the daily lives of children and families around the world, which has been associated with various mental health challenges among youth. However, a new study from the Environmental influences on Child Health Outcomes (ECHO) Program at the National Institutes of Health presents a more nuanced picture, suggesting that…

Read More

Current Evidence Does Not Support Link Between Unsaturated Fatty Acids and ADHD

Results of a Mendelian randomization study, published in the Journal of Attention Disorders, did not support a causal relationship between circulating unsaturated fatty acid (UFA) levels and attention-deficit/hyperactivity disorder (ADHD). Although previous evidence has demonstrated that UFAs are essential nutrients for neurodevelopment, brain function, and mental health, it remains unclear as to whether the concentration…

Read More

Therapists Explain How to Manage Your ADHD

PEOPLE MIGHT CLAIM to have ADHD when they’re having an off day, they struggle to concentrate, or forget to do something. However, truly dealing with attention deficit hyperactivity disorder involves a lifelong battle with attention, organization, memory, and impulse control.

Read More